Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Glenmark Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Outcome of Operations Committee Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on July 14, 2016 allotted 2,000 equity shares to the employee of the Company on exercise of options granted to them pursuant to ESOS 2003. Glenmark gets USFDA final nod for anti-fungal ointment
Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for nystatin and triamcinolone acetonide ointment. Glenmark Pharmaceuticals receives tentative ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated June 24, 2016 titled "Glenmark Pharmaceuticals receives tentative ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg". Glenmark Pharmaceuticals receives ANDA approval for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/1 mg per gram
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated June 24, 2016 titled "Glenmark Pharmaceuticals receives ANDA approval for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/1 mg per gram". Buy Glenmark Pharmaceuticals, target Rs 1,186: Prabhudas Lilladher
Glenmark's shares have taken a cut of 13 per cent so far this year, but Prabhudas Lilladher believes the company can grow on the back of Research & Development investments.
IFC to invest up to $75 million in Glenmark Pharma
Glenmark Pharma is raising the capital by selling quasi-equity instruments Glenmark Pharma losing potency
A fall below 760 can drag the stock down to 700 or 670 levels in the medium term Sell Glenmark Pharma with a target of Rs 825: Mitesh Thacker
Sell Glenmark Pharma with a target of Rs 825 and a stop loss of Rs 862.50 Approval of the Subscription Agreement
Glenmark Pharmaceuticals Ltd has informed BSE that in furtherance to the notice issued by the Company on May 31, 2016 announcing the launch of the FCCBs, the Company has entered into a Subscription Agreement dated May 31, 2016 with J.P. Morgan Securities plc (the book running lead manager to the Issue).In terms of the Subscription Agreement, the Company will issue the FCCBs at 100% of their principal amount on or about June 28, 2016 (Closing Date).